Emerging Data and Future Directions in UC

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS

Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Tim Cortese

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Matthew Fowler;Jun Gong, MD

March 15th 2022

Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Ashling Wahner

Enfortumab Vedotin Combo Improves PFS/OS Vs Chemo in Urothelial Carcinoma

Data from the ENVISION and ATLAS trials demonstrated clinically meaningful responses with UGN-102 in the treatment of low-grade, intermediate-risk NMIBC.

Data from the EV-302 trial support enfortumab vedotin plus pembrolizumab as a new standard of care in frontline urothelial cancer.

Kristi Rosa

Cretostimogene Grenadenorepvec Yields Sustained Antitumor Activity in NMIBC

Data from the EV-302 trial support enfortumab vedotin plus pembrolizumab as a new standard of care in frontline urothelial cancer.

Related Content

Roman Fabbricatore

March 25th 2025

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS

Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Tim Cortese

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.

Matthew Fowler;Jun Gong, MD

March 15th 2022

Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Ashling Wahner

Enfortumab Vedotin Combo Improves PFS/OS Vs Chemo in Urothelial Carcinoma

Data from the ENVISION and ATLAS trials demonstrated clinically meaningful responses with UGN-102 in the treatment of low-grade, intermediate-risk NMIBC.

Kristi Rosa